[Paolyta] Announcement regarding the signing of an authorization agreement for the new drug Nephoxil (Ferric Citrate Capsules) in Mainland China

1. Date of occurrence: June 5, 2026 2. Company Name: Paolyta Co., Ltd. 3. Relationship with the company: The Company 4. Cross-shareholding ratio: Not applicable 5. Reason for occurrence: In response to the application schedule for adjustments to Mainland China's national medical insurance catalog, the board resolved to sign an authorization letter for the new drug Nephoxil (Ferric Citrate Capsules). The counterparty is authorized to act as the responsible person and general agent in Mainland China, managing administrative procedures including online registration, data submission, price negotiations, regulatory compliance, and sales preparations. 6. Countermeasures: Issuance of a major message 7. Other matters: (1) This case is for the purpose of medical insurance filing and market entry preparation, and has no immediate impact on the company's current finances and operations. (2) Summary of the authorization letter: (A) Authorized party: Weigao Dialysis Technology (Weihai) Co., Ltd. (B) Authorization period: Valid for one year from the date of signing. (C) Scope: Exclusive authorization to act as the responsible person and general agent for Nephoxil in Mainland China (excluding Taiwan, Hong Kong, and Macao), handling all administrative procedures for national medical insurance. (3) New drug development takes time and involves high investment, with no guarantee of success. Investors should exercise caution.